Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.77 and traded as high as $1.06. Brainstorm Cell Therapeutics shares last traded at $1.00, with a volume of 4,979 shares changing hands.
Brainstorm Cell Therapeutics Stock Performance
The business has a 50-day moving average of $0.90 and a 200-day moving average of $0.77. The stock has a market capitalization of $11.04 million, a price-to-earnings ratio of -0.30 and a beta of 0.23.
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Featured Articles
- Five stocks we like better than Brainstorm Cell Therapeutics
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
